Navigation Links
Improvements in Recurrence-Free Survival in Early Stages of Colorectal Cancer Will Limit Growth of Drug Treatment Opportunities for Advanced Disease
Date:12/16/2010

BURLINGTON, Mass., Dec. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that projected improvements in recurrence-free survival in early stages of colorectal cancer is the most important factor limiting drug treatment opportunities for advanced disease. According to analysis of Pharmacor Patient Flow Model Colorectal Cancer, the growth in drug treatment opportunities for advanced disease will be limited to 15 percent between 2009 and 2024.

"Drug treatment opportunities for advanced colorectal cancer will be limited because of a sustained decrease in the recurrence risk in early stages of the disease," said Decision Resources Epidemiologist Donal Minihan, M.V.B., Ph.D. "Yet, aging population trends will be responsible for growth in the number of diagnosed incident cases of colorectal cancer in all major markets, resulting in a 27 percent growth in drug treatment opportunities for newly diagnosed cases of colorectal cancer."

The findings are derived from Decision Resources' Pharmacor Patient Flow Models which utilize Decision Resources proprietary suite of epidemiological models. With Pharmacor Patient Flow Models, users can build their own oncology patient flow model and/or validate the assumptions behind their own internal models. This interactive tool allows users to track changing disease and population dynamics over a 15-year annualized forecast, improve their modeling accuracy with clearly depicted methods and transparent assumptions and identify untapped market potential within lines of therapy. Pharmacor Patient Flow Models are available as an add-on product to the Pharmacor advisory service.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
2. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
3. Soliris(R) Demonstrates Reductions in Hemolysis and Improvements in Fatigue, Overall Quality of Life and Anemia in a Broad Population of PNH Patients
4. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
5. Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients
6. Naturally Occurring Compounds in Cocoa Tied to Blood Flow Improvements for Adults With Type 2 Diabetes
7. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
8. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements Over Four Years
11. Study Shows EUFLEXXA(R) Patients Report Significant Improvements in Osteoarthritis of the Knee Pain over a Six Month Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- The Lupus Foundation of America and Eli Lilly ... results from UNVEIL: understanding the impact of lupus, a ... and the challenges not only for those living with ... which involved over 1,000 people with lupus and lupus ... aspects of life including family, work, finances, treatment experiences ...
(Date:9/16/2014)... -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY ), ... and novel medicines to physicians and patients at accessible ... Baum will be a presenter at the 5 ... York City.  Mr. Baum will discuss the company,s growth ... ophthalmology. The presentation is scheduled for 10:40 a.m. EST on ...
(Date:9/16/2014)... 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), a ... chronic pain, announced today that it has entered into ... in a series of animal studies for levorphanol, the ... release form of levorphanol.  Gavril Pasternak, MD, PhD, of ... Dr. Pasternak said, "Levorphanol is a unique ...
Breaking Medicine Technology:"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 2Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 3Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference 4Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3
(Date:9/16/2014)... 15, 2014A prospective study that compared patient-reported outcomes ... bone metastases demonstrates that single fraction radiation therapy ... radiation therapy (MFRT) when pain, function and quality ... today at the American Society for Radiation Oncology,s ... that improvements in patients, pain, function and degree ...
(Date:9/16/2014)... Beginning October 1st 2014, Dallas’ Park Cities Pet ... clients who book a recurring visit schedule, and thus receive ... Most recurring visit clients are ones that book ... include clients whose unique work schedules or lifestyles simply require ... basis. The newly introduced 15-minute visit length will only ...
(Date:9/16/2014)... Founded by former Miami Beach mayoral ... political organization fighting to legalize medical marijuana in Florida. ... After Party recently commissioned a shot-for-shot parody video of ... the movie “Grease.” ( http://youtu.be/zdcvhUgeDRg ) , Called “You’re ... musical parody faithfully recreates the carnival scene made famous ...
(Date:9/16/2014)... September 16, 2014 Florida Hospital announced ... Lightning to extend its partnership and become the Presenting ... as the team’s official health and wellness partner. As ... Hospital will receive a logo and name inclusion on ... two seasons. Florida Hospital has been a sponsorship partner ...
(Date:9/16/2014)... serve of dairy food may reduce the risk of ... foods have not traditionally formed part of the diet. ... by Emeritus Professor Mark Wahlqvist from Monash University,s Department ... Institute, considered the role increased consumption of dairy foods ... longevity. , "In a dominantly Chinese food culture, ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 2Health News:Dallas-based Park Cities Pet Sitter Introduces New 15-Minute Visit for Clients on Recurring Visit Schedules. 3Health News:Miami Beach Politician Drives 1,400 Miles to Texas to Shoot “Grease” Parody Video Supporting the Legalization of Medical Marijuana in Florida 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 2Health News:Florida Hospital Teams up with the Tampa Bay Lightning as the New Presenting Sponsor of the 2014-15 and 2015-16 Lightning Seasons 3Health News:A heart-felt need for dairy food 2
... Brunswick are facing one of the worst gastroenteritis epidemics ... gear, with patients coming// in droves for relief. The ... continue for a few days but seldom endangers life. ... greater Montreal area have reported the viral outbreak. Dr. ...
... nutrient folate through both diet and supplements may have ... a report in the January issue of Archives of ... year 2047, the prevalence of Alzheimer’s disease is expected ... Delaying the onset of this neurodegenerative disease would significantly ...
... fight malaria in Africa has received its first-ever challenge ... pledge// to match dollar for dollar up to $3 ... a disease that kills more than 1 million people ... ‘Nothing But Nets’ campaign, a partnership between the UN ...
... Welcome to another cold season. If you’re like most adults, ... especially preschoolers, have it worse//, getting as many as eight ... Mayo Clinic Women’s HealthSource offers insights on how you can ... ,It’s a virus, not the temperature, that causes colds. ...
... to improve the treatment given to people bitten by snakes or ... ,Africa, Latin America and Asia are the most affected ... it comes to snake bite, the actual number of death is ... intervention. ,According to a WHO release, rabies figures tenth ...
... disease. Yet recent studies have shown that the chance of ... and exercise//, the chances of surviving it, also depend on ... putting around 50,000 pounds behind a study to be carried ... will involve cancer survivors aged above fifty and with a ...
Cached Medicine News:Health News:Higher Folate Levels Linked to Reduced Risk for Alzheimer’s Diseas 2Health News:Yes, Chicken Soup Can Help 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: